Reducing the Cost of Goods and Environmental Impact

The AbYlink technology enables a seamless, reproducible conjugation of payloads to antibodies or ADCs.

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

The commitment will include new, state-of-the-art R&D facilities as well as new or expanded manufacturing sites in multiple states.

Vitrakvi (larotrectinib) was first granted accelerated approval by FDA in November 2018.